Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer

Hosoda Mitsuchika; Yamamoto Mitsugu; Nakano Kiichiroh; Hatanaka Kanako C.; Takakuwa Emi; Hatanaka Yutaka; Matsuno Yoshihiro; Yamashita Hiroko

タイトル	en Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer
作成者	en Hosoda, Mitsuchika NRID 1000040443931 en Yamamoto, Mitsugu en Nakano, Kiichiroh en Hatanaka, Kanako C. en Takakuwa, Emi en Hatanaka, Yutaka NRID 1000030589924 en Matsuno, Yoshihiro en Yamashita, Hiroko NRID 1000070332947
アクセス権	open access
権利情報	en The final publication is available at link.springer.com
主題	Other en Breast cancer Other en Progesterone receptor Other en FOXA1 Other en GATA3 Other en Ki67 Other en p53 NDC 495
内容注記	Abstract en Estrogen receptor (ER) is essential for estrogendependent growth, and its level of expression is considered a crucial determinant of response to endocrine therapy and prognosis in ER-positive breast cancer. On the other hand, the clinical role of progesterone receptor (PgR) in ER-positive breast cancer remains controversial, although testing of PgR by immunohistochemistry (IHC) has become routine. Recent studies indicated that plasma estradiol levelswere related to the expression levels of estrogen-responsive genes in ER-positive breast cancer tissues in both pre- and postmenopausal women. In this study, we analyzed the expression levels of strogenresponsive genes (PgR and TFF1), a progesterone-responsive gene (RANKL), ER-related genes (FOXA1 and GATA3), HER2, Ki67 and p53 in ER-positive, HER2-negative breast cancer tissues by IHC. Correlations between the expression levels of these molecular markers and clinicopathological factors, including prognosis, were compared between pre- and postmenopausal women. Serum levels of estrone, estradiol, progesterone, and testosterone were also measured. Expression levels of PgR, TFF1, RANKL, and GATA3 were significantly higher in premenopausal women than in postmenopausal women. Serum estradiol levels were positively correlated with Ki67 labeling index (LI) in premenopausal women, but not in postmenopausal women. High expression of FOXA1 and GATA3 was significantly associated with improved diseasefree survival in premenopausal women, but not in postmenopausal women, whereas high expression of PgR and low expression of p53 were significantly correlated with the improved disease-free survival in postmenopausalwomen, but not in premenopausalwomen.Moreover, the best cutoff points of Ki67 LI for disease-free survival were 30 % for premenopausal women and 14 % for postmenopausal women. Expression levels of ER, TFF1, and RANKL were not associated with the disease-free survival in either pre- or postmenopausal women. Our results suggest that the mechanisms of development and estrogen-dependent growth ofER-positive breast cancer might differ according to menopausal status.
出版者	en Springer
日付	Issued2014-04
言語	eng
資源タイプ	journal article
出版タイプ	AM
資源識別子	HDL http://hdl.handle.net/2115/58539
関連	isVersionOf DOI https://doi.org/10.1007/s10549-014-2867-0 PMID 24549642
収録誌情報	PISSN 0167-6806 EISSN 1573-7217 NCID AA10623184 en Breast Cancer Research and Treatment 巻144 号2 開始ページ249 終了ページ261
ファイル	fulltext Breast Cancer Res Treat_144(2)_249-261.pdf 3.39 MB (application/pdf) Issued2014-04
コンテンツ更新日時	2023-07-26